Literature DB >> 302316

Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.

L H Perrin, R M Zinkernagel, M B Oldstone.   

Abstract

After vaccinia virus vaccination of human volunteers, local indurations developed within 10 days, and regional adenopathy was detected in half of the individuals. Their peripheral blood lymphocytes (PBL) harvested at different days after vaccination showed specific activity against target cells infected with vaccinia virus with a peak activity at day 7. The specificity of the cytotoxic activity was not related to HLA markers, since autologous, homologous, and heterologous infected target cells were lysed with the same efficiency. The cytotoxic activity was caused by PBL that did not rosette with sheep erythrocytes and could be depleted by more than 90 percent by removing Fc receptor-bearing cells. T-cell- depleted PBL showed a one-half to two times greater cytotoxicity than intact PBL. The cytotoxic activity could also be abrogated by more than 95 percent by rabbit Fab(2) anti-human IgG. On the other hand, nonimmune PBL lysed vaccinia-infected target cells in the presence of specific antibodies against vaccinia virus, thus demonstrating that ADCC could be efficient in lysing vaccinia-infected target cells. We conclude that after vaccination, antibody-forming cells arise and provide specific anti-viral antibody and that the cytotoxic cells detected in this reaction are K cells. These experiments suggest that antibody-dependent cell cytotoxicity may be of major importance in the recovery of man to virus infections.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 302316      PMCID: PMC2180809          DOI: 10.1084/jem.146.4.949

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  45 in total

Review 1.  ASPECTS OF THE PATHOGENESIS OF VIRUS DISEASES.

Authors:  C A MIMS
Journal:  Bacteriol Rev       Date:  1964-03

2.  Purification of pox viruses by density gradient centrifugation.

Authors:  H T ZWARTOUW; J C WESTWOOD; G APPLEYARD
Journal:  J Gen Microbiol       Date:  1962-11

3.  A plaque neutralization method for arboviruses.

Authors:  E Earley; P H Peralta; K M Johnson
Journal:  Proc Soc Exp Biol Med       Date:  1967-07

4.  Lysis of cytomegalovirus-infected human fibroblasts and transformed human cells by peripheral blood lymphoid cells from normal human donors.

Authors:  R D Diamond; R Keller; G Lee; D Finkel
Journal:  Proc Soc Exp Biol Med       Date:  1977-02

5.  Cooperation between mouse T-cell subpopulations in the cell-mediated response to a natural poxvirus pathogen.

Authors:  T Pang; I F McKenzie; R V Blanden
Journal:  Cell Immunol       Date:  1976-10       Impact factor: 4.868

6.  Immunological deficiency diseases. Agammaglobulinemia, hypogammaglobulinemia, Hodgkin's disease and sarcoidosis.

Authors:  R A GOOD; W D KELLY; J ROTSTEIN; R L VARCO
Journal:  Prog Allergy       Date:  1962

7.  Fibroblast lysis by lymphocytes from normal persons and SLE patients on short-term cultures.

Authors:  E M Liburd; V Pazderka; A S Russell; J B Dossetor
Journal:  Immunology       Date:  1976-11       Impact factor: 7.397

8.  The mammalian cell-virus relationship. I. Attachment of poliovirus to cultivated cells of primate and non-primate origin.

Authors:  L C McLAREN; J J HOLLAND; J T SYVERTON
Journal:  J Exp Med       Date:  1959-05-01       Impact factor: 14.307

9.  Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled.

Authors:  R M Zinkernagel; A Althage
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

10.  Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.

Authors:  L Moretta; S R Webb; C E Grossi; P M Lydyard; M D Cooper
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307

View more
  26 in total

Review 1.  Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease.

Authors:  A J McMichael
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Role of T lymphocytes in cellular immune responses during herpes simplex virus infection in humans.

Authors:  L Rasmussen; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

3.  Accumulation of thyroid antigen-reactive T lymphocytes in the gland of patients with subacute thyroiditis.

Authors:  T H Tötterman; A Gordin; P Häyry; L C Andersson; T Makinen
Journal:  Clin Exp Immunol       Date:  1978-04       Impact factor: 4.330

4.  Lymphocyte-mediated cytotoxicity in humans during revaccination with vaccinia virus.

Authors:  A Møller-Larsen; S Haahr; I Heron
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

Review 5.  Rheumatoid arthritis--a virus disease?

Authors:  A M Denman
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1978

Review 6.  HIV antibodies for treatment of HIV infection.

Authors:  David M Margolis; Richard A Koup; Guido Ferrari
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Vaccinia virus-specific human CD4+ cytotoxic T-lymphocyte clones.

Authors:  R A Littaua; A Takeda; J Cruz; F A Ennis
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

8.  Cell cytotoxicity due to specific influenza antibody production in vitro after recent influenza antigen stimulation.

Authors:  S B Greenberg; H R Six; S Drake; R B Couch
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

9.  Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice: natural killer cell activity in cultured spleen leukocytes concomitant with T-cell-dependent immune interferon production.

Authors:  R M Welsh; W F Doe
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

10.  Vaccinia virus-specific CD8+ cytotoxic T lymphocytes in humans.

Authors:  W E Demkowicz; F A Ennis
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.